Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Capital Expenditures (2019 - 2025)

Historic Capital Expenditures for AVITA Medical (RCEL) over the last 7 years, with Q4 2025 value amounting to -$2.7 million.

  • AVITA Medical's Capital Expenditures rose 8395.7% to -$2.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.0 million, marking a year-over-year increase of 8904.15%. This contributed to the annual value of -$1.0 million for FY2025, which is 8904.15% up from last year.
  • Per AVITA Medical's latest filing, its Capital Expenditures stood at -$2.7 million for Q4 2025, which was up 8395.7% from $934000.0 recorded in Q3 2025.
  • In the past 5 years, AVITA Medical's Capital Expenditures ranged from a high of $3.8 million in Q3 2024 and a low of -$16.7 million during Q4 2024
  • For the 5-year period, AVITA Medical's Capital Expenditures averaged around -$447666.7, with its median value being $297500.0 (2023).
  • The largest annual percentage gain for AVITA Medical's Capital Expenditures in the last 5 years was 78695.65% (2024), contrasted with its biggest fall of 575202.7% (2024).
  • AVITA Medical's Capital Expenditures (Quarter) stood at $67000.0 in 2021, then grew by 4.48% to $70000.0 in 2022, then surged by 322.86% to $296000.0 in 2023, then plummeted by 5752.03% to -$16.7 million in 2024, then soared by 83.96% to -$2.7 million in 2025.
  • Its Capital Expenditures was -$2.7 million in Q4 2025, compared to $934000.0 in Q3 2025 and $524000.0 in Q2 2025.